Hims & Hers Health vs Meta
Side-by-side comparison of AI visibility scores, market position, and capabilities
Telehealth platform with $872M 2024 revenue; GLP-1 weight loss, hair, and sexual health prescriptions shipped directly to 2M+ subscribers; went public via SPAC merger in 2021; compounded medications and same-day shipping differentiate from traditional telehealth.
About
Hims & Hers Health is a telehealth and wellness platform offering personalized treatment plans and prescription medications for conditions including hair loss, erectile dysfunction, weight management, skincare, and mental health. Founded in 2017 and headquartered in San Francisco, Hims & Hers went public via SPAC merger in January 2021 and has grown into a $1B+ revenue publicly traded health company. The platform connects patients with licensed providers asynchronously and ships prescription treatments directly to homes, eliminating the friction of in-person doctor visits for lifestyle health conditions.
Llama 4 open-source model (Scout, Maverick, Behemoth) released March 2026; Meta AI assistant deployed to 700M+ users across WhatsApp, Instagram, Facebook. FAIR research driving multimodal AI advances; $35B AI capex in 2025.
About
Meta Platforms is a Menlo Park, California-based technology conglomerate operating the world's most widely used social media ecosystem — Facebook (3+ billion monthly active users), Instagram (2+ billion MAU), WhatsApp (2.8+ billion MAU), and Threads (launched 2023) — while investing heavily in virtual reality hardware (Meta Quest), augmented reality glasses (Meta Ray-Ban, Orion AR glasses in development), and AI research (Llama open-source model family). Listed on NASDAQ (NASDAQ: META), Meta generated $164.5 billion in revenue in fiscal year 2024 and employs approximately 74,000 people globally.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.